Navigation Links
Covance Establishes New Discovery & Translational Services Group


PRINCETON, N.J., May 10 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), a leading provider of drug R&D services, announced today that it has created a new Discovery & Translational Services group, which will integrate its discovery services, antibody products and immunology services, Biomarker Center of Excellence, and Genomics Laboratory. Leveraging its minority equity stake in Caprion Proteomics, Inc. and alliance with Rules-Based Medicine, Inc., Covance's Discovery & Translational Services group will offer clients a depth and breadth of drug discovery and biomarker services that is unmatched in the CRO industry.

"Increasingly our clients are looking for drug development companies that can provide a full spectrum of services and expertise from early drug discovery through late-stage clinical trials and post-marketing surveillance," said Joe Herring, Chairman and Chief Executive Officer of Covance Inc. "Through a series of strategic investments and alliances, we have enhanced our early-stage drug R&D capabilities and gained an impressive array of world-class talent and technologies in genomics, proteomics, biomarkers, and discovery services such as early safety and efficacy testing, in vivo pharmacology and imaging. As a result, Covance now has a comprehensive range of integrated services across the drug R&D continuum that can help clients make faster and more effective decisions about their portfolios."

Discovery & Translational Services will report to Deborah Tanner, Corporate Senior Vice President at Covance; President, Central Laboratory Services and President, Discovery & Translational Services. Said Ms. Tanner, "By uniting our discovery and translational services under one operating umbrella we can better leverage current capabilities, foster greater scientific and technical collaboration, and ultimately provide greater value to our clients through a portfolio of services that parallel their drug development model."

Jonathan Koch has been appointed Vice President and General Manager, Discovery & Translational Services.  Mr. Koch most recently held the position of Vice President and General Manager for the Covance Greenfield, Indiana campus.

With its Discovery and Translational Services group Covance is uniquely positioned to provide clients with an integrated set of discovery capabilities and leverage a range of translational tools such as imaging, biomarkers and genomics across its broad portfolio of development services.  "Our goal is to generate data that yields more effective results for clients," said Dr. Tom Turi, Vice President, Science and Technology for Discovery and Translational Services.  "Through our enhanced discovery services we are able to provide clients with decision-driving information earlier in, and throughout, the drug development process."

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.8 billion, global operations in more than 30 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.

SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Covance Establishes New Discovery & Translational Services Group
2. Innovalight Establishes New Record With Silicon Ink Solar Cells
3. DFG establishes 10 new research units
4. TGen Drug Development establishes European footprint
5. March of Dimes establishes 2 new perinatal bioethics awards
6. MU research team establishes family tree for cattle, other ruminants
7. $29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation
8. The last supper of the hominids establishes the times they lived at the sites
9. UBC study establishes formula for predicting climate change impact on salmon stocks
10. Rice University establishes National Corrosion Center
11. Sharper image: UH optometrist establishes sports vision clinic
Post Your Comments:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of the year and one of the premier annual events for pharmaceutical manufacturing: ... from 8–11 November 2015, where ISPE hosted the largest number of attendees in ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology: